Oncotelic Therapeutics Reports $249 Million Net Income for Fiscal Year 2025

Oncotelic Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025, with net income of approximately $249.0 million compared to a net loss of $4.8 million in the previous fiscal year. The clinical-stage biopharmaceutical company, which focuses on orphan oncology and advanced drug platforms, attributed this substantial improvement primarily to a non-cash gain of approximately $365.4 million from the increased valuation of its GMP Biotechnology joint venture.

The company’s financial results were partially offset by a deferred tax provision of $111.6 million. Oncotelic conducts business activities through its wholly-owned subsidiaries including Oncotelic, Inc., PointR Data, Inc., Pet2DAO, Inc., and EdgePoint AI, Inc., with the latter having non-controlling interests. The company’s principal corporate office is located in Agoura Hills, California.

Oncotelic is currently developing OT-101 along with five additional compounds for various cancers and COVID-19 through its joint venture GMP Bio. According to the company’s announcement, GMP Bio is developing five additional nanoparticle compounds in the joint venture, which has the potential for significant revenues and value. The company also acquired apomorphine for Parkinson’s Disease, erectile dysfunction and female sexual dysfunction.

Additional development activities include evaluating OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes, and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. The company is planning to address the animal health industry through Pet2DAO. More information about the company is available at https://www.oncotelic.com.

The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC. The financial announcement was distributed through BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN that provides various distribution services including access to wire solutions, article syndication to over 5,000 outlets, press release enhancement, and social media distribution. More information about BioMedWire is available at https://www.BioMedWire.com.

The financial results represent a significant turnaround for Oncotelic, which changed its name from Mateon Therapeutics, Inc. in November 2020. The company was originally formed in 1988 as OXiGENE, Inc. and was reincorporated in Delaware in 1992 before becoming Mateon Therapeutics in 2016. The substantial non-cash gain from the GMP Biotechnology joint venture valuation highlights the potential value of the company’s partnership and development pipeline while the deferred tax provision reflects accounting requirements related to the valuation increase.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Reports $249 Million Net Income for Fiscal Year 2025.

The post Oncotelic Therapeutics Reports $249 Million Net Income for Fiscal Year 2025 appeared first on citybuzz.